ð¥ ãããèåããç
æ°ã ãšãããââ
ããã¯æ²»çã§ããã
ãã㯠SF ã§ã¯ãããŸãããããŒããŒã倧åŠå»åŠéšã® David Sinclair ææããäžççãã¹ãã»ã©ãŒãLIFESPANãã§äž»åŒµããŠããç§åŠçäºå®ã§ãã
ãã®éµãæ¡ãã®ãããµãŒãã¥ã€ã³éºäŒåïŒSirtuinïŒãââéç§°ãé·å¯¿éºäŒåãã
ãã®èšäºã§ã¯ããµãŒãã¥ã€ã³éºäŒåãšã¯äœãããªãèåãæ¢ããããã®ãããããŠã©ãããã°æŽ»æ§åã§ããã®ãããææ°ã®ç§åŠç ç©¶ã«åºã¥ããŠåŸ¹åºè§£èª¬ããŸãã
â ãã®èšäºã§ãããããš
ã»ãµãŒãã¥ã€ã³éºäŒåãšã¯äœãïŒãªããé·å¯¿éºäŒåããšåŒã°ããã®ã
ã»ãµãŒãã¥ã€ã³ãèåãé転ãããã¡ã«ããºã
ã»æŽ»æ§åãã7ã€ã®æ¹æ³ïŒéåã»æé£ã»ãµããªã»ç¡ç etc.ïŒ
ã»NMNãµããªã¯æ¬åœã«å¹ãã®ãïŒç§åŠçãšããã³ã¹ã®æ€èšŒ
ã»ä»æ¥ããå§ããããããµãŒãã¥ã€ã³æŽ»æ§åã«ãŒãã£ã³ã
ð ç®æ¬¡ïŒã¯ãªãã¯ã§ãžã£ã³ãïŒ
1. ãµãŒãã¥ã€ã³éºäŒåãšã¯ïŒçºèŠã®æŽå²ãšåºç€ç¥è
2. ãªããµãŒãã¥ã€ã³ã¯ãé·å¯¿éºäŒåããšåŒã°ããã®ã
3. èåã®ã¡ã«ããºã ãšãµãŒãã¥ã€ã³ã®åœ¹å²
4. ãå®å
šçããµãŒãã¥ã€ã³éºäŒåãæŽ»æ§åãã7ã€ã®æ¹æ³
5. NMNãµããªã¡ã³ãã®çå®ââ广ã»å¯äœçšã»éžã³æ¹
6. éå vs ãµã㪠vs æé£ïŒã©ããæã广çãïŒ
7. 仿¥ããå§ããããµãŒãã¥ã€ã³æŽ»æ§åã«ãŒãã£ã³ã
8. ãŸãšãïŒèåã¯éžæã§ãã
𧬠1. ãµãŒãã¥ã€ã³éºäŒåãšã¯ïŒçºèŠã®æŽå²ãšåºç€ç¥è
ãµãŒãã¥ã€ã³éºäŒåïŒSirtuinïŒãšã¯ãã»ãŒãã¹ãŠã®çç©ã«ååšããé·å¯¿ã«é¢ããéºäŒå矀ã§ããé µæ¯ãããããŸã§é²åã®éçšã§ä¿åãããŠããããšãããçåœã«ãšã£ãŠæ¥µããŠéèŠãªåœ¹å²ãæ ã£ãŠãããšèããããŠããŸãã
ð ãµãŒãã¥ã€ã³éºäŒåã®åºæ¬ããŒã¿
7çš®é¡
ããã®ãµãŒãã¥ã€ã³
ïŒSIRT1ãSIRT7ïŒ
1999幎
é·å¯¿å¹æã®çºèŠ
ïŒMITã»Leonard GuarenteïŒ
NAD+
掻æ§åã«å¿
èŠãªè£é
µçŽ
ïŒå éœ¢ã§æžå°ïŒ
ð çºèŠã®æŽå²ïŒãªããé·å¯¿éºäŒåããšåŒã°ããããã«ãªã£ãã
1999幎ïŒMITã®Leonard Guarenteææããé
µæ¯ã®SIR2éºäŒåãæŽ»æ§åãããšå¯¿åœã30%å»¶é·ããããšãçºèŠã
2003幎ïŒDavid SinclairææïŒåœæGuarenteã®ç 究宀ïŒããèµ€ã¯ã€ã³ã«å«ãŸããã¬ã¹ãã©ãããŒã«ãSIRT1ãæŽ»æ§åããããšãçºèŠã
2013幎ïŒSinclairãNMNïŒãã³ãã³ã¢ããã¢ããã¯ã¬ãªããïŒæäžã§èåããŠã¹ãè¥è¿ã£ããšå ±åããäžççãªæ³šç®ãéããã
2019幎ïŒSinclairèãLIFESPANïŒã©ã€ãã¹ãã³ïŒãããã¹ãã»ã©ãŒã«ããèåã¯ç
æ°ã§ããããšããæŠå¿µãäžè¬ã«åºãŸãã
ð¬ ããã®7çš®é¡ã®ãµãŒãã¥ã€ã³
| çš®é¡ | ååšå Žæ | äž»ãªæ©èœ |
|---|---|---|
| SIRT1 | æ žã»çްè質 | 代è¬èª¿æŽãDNA修埩ãççæå¶ïŒæãç ç©¶ãããŠããïŒ |
| SIRT2 | 现è質 | 现èåšæå¶åŸ¡ãèèªä»£è¬ |
| SIRT3 | ããã³ã³ããªã¢ | ãšãã«ã®ãŒä»£è¬ãé žåã¹ãã¬ã¹é²åŸ¡ |
| SIRT4 | ããã³ã³ããªã¢ | ã€ã³ã¹ãªã³åæ³èª¿æŽãèèªé žä»£è¬ |
| SIRT5 | ããã³ã³ããªã¢ | å°¿çŽ åè·¯ãè§£æ¯äœçš |
| SIRT6 | æ ž | DNA修埩ãããã¡ã¢ç¶æãè¡ç³èª¿æŽ |
| SIRT7 | æ žå°äœ | ãªããœãŒã çåæãã¹ãã¬ã¹å¿ç |
ð¡ ãã€ã³ãïŒãµãŒãã¥ã€ã³ã¯åãªããé·å¯¿éºäŒåãã§ã¯ãããŸããã代è¬ã»DNA修埩ã»ççæå¶ã»ã¹ãã¬ã¹å¿çãªã©ãçåœç¶æã«äžå¯æ¬ ãªå€ãã®æ©èœãæ ãã现èã®å®è·è ããªã®ã§ãã
â³ 2. ãªããµãŒãã¥ã€ã³ã¯ãé·å¯¿éºäŒåããšåŒã°ããã®ã
ãµãŒãã¥ã€ã³éºäŒåããé·å¯¿éºäŒåããšåŒã°ããçç±ââããã¯ãããããçç©ã§ãµãŒãã¥ã€ã³ã掻æ§åãããšå¯¿åœãå»¶é·ãããšããé©ãã¹ãç ç©¶çµæããç¹°ãè¿ãå ±åãããŠããããã§ãã
ð ãµãŒãã¥ã€ã³æŽ»æ§åã«ãã寿åœå»¶é·ããŒã¿
ð§« é µæ¯
+30%
SIR2éå°çºçŸ
𪱠ç·è«
+50%
SIR-2.1掻æ§å
ð ããŠã¹
+16%
SIRT6éå°çºçŸ
ð§ ããïŒæåŸ ïŒ
?
èšåºè©Šéšé²è¡äž
ð¡ïž ãµãŒãã¥ã€ã³ã寿åœãå»¶ã°ã3ã€ã®ã¡ã«ããºã
DNA修埩
ãµãŒãã¥ã€ã³ã¯DNAã®æå·éšäœã«éãŸããä¿®åŸ©é µçŽ ããªã¯ã«ãŒãã现èã®ã²ãã å®å®æ§ãç¶æããããåãé²ãã
代è¬èª¿æŽ
ããã³ã³ããªã¢æ©èœãæé©åãããšãã«ã®ãŒå¹çãåäžãèèªççŒãä¿é²ããç³ä»£è¬ãæ¹åããã
ççæå¶
æ ¢æ§ççïŒèåã®æå€§èŠå ã®1ã€ïŒãæå¶ãNF-κBãªã©ã®çççµè·¯ãå¶åŸ¡ããçµç¹ã®ãã¡ãŒãžã軜æžã
åºå ž: Guarente L. “Sirtuins, aging, and metabolism.” Cold Spring Harb Symp Quant Biol. 2011 / Kanfi Y, et al. “The sirtuin SIRT6 regulates lifespan in male mice.” Nature. 2012
ð¬ 3. èåã®ã¡ã«ããºã ãšãµãŒãã¥ã€ã³ã®åœ¹å²
David Sinclairææã¯ãèåããæ å ±ã®åªå€±ããšããŠæããŠããŸããDNAãã®ãã®ã¯å€ãããªããŠãããã©ã®éºäŒåããã€èªã¿åããããšãããšããžã§ããã£ãã¯æ å ±ãä¹±ããããšã§ã现èã¯æ£åžžãªæ©èœã倱ã£ãŠããââãããèåã®æ¬è³ªã ãšèšãã®ã§ãã
ð¡ èåã®æ°çè«ïŒãšããžã§ããã£ã¯ã¹ä»®èª¬
ð¹ ãã¢ãã®äŸãã§çè§£ããïŒ
DNAããæ¥œèãã ãšãããšããšããžã§ããã£ã¯ã¹ã¯ãã©ã®é³ããã€åŒŸããããšããæŒå¥æ
å ±ã
è¥ã现èã¯æ¥œèéãã«çŸããæŒå¥ãã§ããŸãããèåãã现èã¯ãã©ãã匟ãã¹ããããããããªããªããäžååé³ïŒèåçç¶ïŒãåºãå§ããŸãã
ãµãŒãã¥ã€ã³ã¯ããã®ãæŒå¥æ
å ±ãæ£ããä¿ã€åœ¹å²ããæ
ã£ãŠããŸãã
èåã¯ãéºäŒåã®æå·ãã§ã¯ãªããéºäŒåã®èªã¿åããšã©ãŒãâ 修埩å¯èœ
ð ãµãŒãã¥ã€ã³ã®ãçæãïŒNAD+
ãµãŒãã¥ã€ã³ãåãããã«ã¯NAD+ïŒãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãªããïŒãšããè£é
µçŽ ãå¿
èŠã§ãã
ãããNAD+ã¯å 霢ãšãšãã«æžå°ââããããµãŒãã¥ã€ã³æŽ»æ§äœäžã®äž»å ã
20æ³
100%
40æ³
ã50%
60æ³
ã25%
NAD+ãå¢ãã = ãµãŒãã¥ã€ã³ã掻æ§å = èåãé ãããïŒé転ãããïŒïŒ
â ïž éèŠïŒãµãŒãã¥ã€ã³ã¯åžžã«æŽ»æ§åãããŠããããã§ã¯ãããŸããã现èããã¹ãã¬ã¹ããæç¥ãããšãã«ã¹ã€ãããå ¥ããŸããããããæé£ã»éåã»å¯å·åºæ¿ããµãŒãã¥ã€ã³ã掻æ§åããçç±ã§ãã
ð 4.ãå®å šçããµãŒãã¥ã€ã³éºäŒåãæŽ»æ§åãã7ã€ã®æ¹æ³
ããããæ¬é¡ããµãŒãã¥ã€ã³éºäŒåãæŽ»æ§åããç§åŠçã«èšŒæããã7ã€ã®æ¹æ³ãã广ã®é«ãé ã«ç޹ä»ããŸãã
ã«ããªãŒå¶éã»æé£ïŒãã¡ã¹ãã£ã³ã°ïŒ
ãµãŒãã¥ã€ã³æŽ»æ§åã®ãçéã
ãªãå¹ãã®ãïŒ
空è
¹ç¶æ
ã«ãªããšã现èã¯ããšãã«ã®ãŒå±æ©ããæç¥ããµãã€ãã«ã¢ãŒãã«å
¥ãããµãŒãã¥ã€ã³ã掻æ§åããŠçްèã®ä¿®åŸ©ã»ä¿è·ãéå§ããŸããããã¯é²åã®éçšã§ç²åŸããã飢é€ãžã®é©å¿æ©æ§ãã§ãã
ð æšå¥šæ¹æ³
ã»16:8æé£ïŒ16æéæé£ã8æéã§é£äº
ã»5:2ãã€ãšããïŒé±2æ¥ã500kcal以äžã«
ã»OMADïŒ1æ¥1é£ïŒäžçŽè
åãïŒ
â¡ å¹æ
ã»SIRT1æŽ»æ§ +200ã300%
ã»ãªãŒããã¡ãžãŒä¿é²
ã»ã€ã³ã¹ãªã³æåæ§åäž
ã»èèªççŒä¿é²
åºå ž: Haigis MC, Sinclair DA. “Mammalian sirtuins: biological insights and disease relevance.” Annu Rev Pathol. 2010
éåïŒç¹ã«é«åŒ·åºŠã€ã³ã¿ãŒãã«éåïŒ
NAD+ãå¢ãããããã³ã³ããªã¢ã掻æ§å
ãªãå¹ãã®ãïŒ
éåã«ããããšãã«ã®ãŒæ¶è²»ã¹ãã¬ã¹ããAMPKãæŽ»æ§åãããããSIRT1ã®æŽ»æ§ãé«ããŸããç¹ã«HIITïŒé«åŒ·åºŠã€ã³ã¿ãŒãã«éåïŒã¯ãçæéã§æå€§ã®å¹æãçºæ®ãçãã¬ã¯SIRT3ïŒããã³ã³ããªã¢ïŒã掻æ§åã
ð æšå¥šéå
ã»HIITïŒé±2-3åã20-30å
ã»çåãã¬ãŒãã³ã°ïŒé±2-3å
ã»æé
žçŽ éåïŒé±150å以äž
ã»ããã¯ãã¯ã·ã³ã°ïŒHIIT+çãã¬å¹æ
â¡ å¹æ
ã»NAD+ã¬ãã«äžæ
ã»SIRT1ã»SIRT3掻æ§å
ã»ããã³ã³ããªã¢æ°ç
ã»BDNFïŒè³ç¥çµæ é€å åïŒå¢å
åºå ž: Cantó C, et al. “AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.” Nature. 2009
NMN / NRãµããªã¡ã³ã
NAD+ã®åé§äœãçŽæ¥è£çµŠ
ãªãå¹ãã®ãïŒ
NMNïŒãã³ãã³ã¢ããã¢ããã¯ã¬ãªããïŒãNRïŒãã³ãã³ã¢ãããªãã·ãïŒã¯ãäœå
ã§NAD+ã«å€æãããŸããå éœ¢ã§æžå°ããNAD+ãçŽæ¥è£çµŠããããšã§ããµãŒãã¥ã€ã³ã®ãçæããäŸçµŠããŸãã
â ïž æ³šæïŒNMNã®é·æçãªå®å šæ§ã»å¹æã¯ãŸã ç 究段éã§ããããŠã¹å®éšã§ã¯åçãªå¹æãå ±åãããŠããŸãããããã§ã®å€§èŠæš¡èšåºè©Šéšã¯éãããŠããŸãã詳现ã¯ã»ã¯ã·ã§ã³5ã§è§£èª¬ããŸãã
ð æšå¥šæåé
ã»NMNïŒ250-500mg/æ¥ïŒç ç©¶ããŒã¹ïŒ
ã»NRïŒ250-300mg/æ¥
ã»æã®ç©ºè
¹æã«æåã广ç
â¡ å ±åãããŠãã广
ã»NAD+ã¬ãã«äžæ
ã»ãšãã«ã®ãŒå¢å æ
ã»éåèæ§åäž
ã»ç¡ç ã®è³ªæ¹åïŒäžéšå ±åïŒ
å¯å·åºæ¿ïŒã³ãŒã«ãã»ã©ããŒïŒ
è€è²èèªçްèãšãµãŒãã¥ã€ã³ã掻æ§å
ãªãå¹ãã®ãïŒ
å¯ããšããã¹ãã¬ã¹ã«å¯ŸããŠãäœã¯ç±ãç£çããããšããŸãããã®ãšãè€è²èèªçްèãæŽ»æ§åããSIRT1ã»SIRT3ãåããŠããã³ã³ããªã¢ã§ã®ç±ç£çïŒUCP1ïŒãä¿é²ãããŸãã
ð§ å®è·µæ¹æ³
ã»å·æ°Žã·ã£ã¯ãŒïŒæåŸ30ç§ã2å
ã»ã¢ã€ã¹ãã¹ïŒ10-15âã§2-5å
ã»å¯ãç°å¢ã§ã®è»œè£
ïŒ18â以äž
â¡ å¹æ
ã»è€è²èèªæŽ»æ§å
ã»ä»£è¬åäžïŒã+15%ïŒ
ã»ççããŒã«ãŒäœäž
ã»ã¡ã³ã¿ã«åŒ·å
è¯è³ªãªç¡ç ïŒ7-8æéïŒ
ãµãŒã«ãã£ã¢ã³ãªãºã ãšãµãŒãã¥ã€ã³ã®åæ
ãªãå¹ãã®ãïŒ
ãµãŒãã¥ã€ã³ã¯äœå
æèšïŒãµãŒã«ãã£ã¢ã³ãªãºã ïŒãšå¯æ¥ã«é£æºããŠããŸããSIRT1ã¯æèšéºäŒåBMAL1ã»CLOCK1ãšçžäºäœçšããç¡ç äžã®DNA修埩ã»çްèåçãæé©åãç¡ç äžè¶³ã¯NAD+代è¬ãä¹±ãããµãŒãã¥ã€ã³æŽ»æ§ãäœäžãããŸãã
ðŽ æšå¥š
ã»7-8æéã®é£ç¶ç¡ç
ã»22:00-6:00ã®ãŽãŒã«ãã³ã¿ã€ã
ã»æ¯æ¥åãæéã«å°±å¯ã»èµ·åº
â¡ å¹æ
ã»DNAä¿®åŸ©ã®æé©å
ã»æé·ãã«ã¢ã³åæ³
ã»NAD+代è¬ã®æ£åžžå
ã»ççããŒã«ãŒäœäž
ããªãã§ããŒã«ïŒã¬ã¹ãã©ãããŒã«çïŒ
èµ€ã¯ã€ã³ã»ããªãŒé¡ã«å«ãŸããå€©ç¶æå
ãªãå¹ãã®ãïŒ
ã¬ã¹ãã©ãããŒã«ã¯2003幎ã«David SinclairããSIRT1掻æ§åç©è³ªããšããŠå ±åããäžèºæåã«ãªã£ãæåãæ€ç©ã玫å€ç·ãªã©ã®ã¹ãã¬ã¹ãã身ãå®ãããã«äœãç©è³ªã§ã人äœã§ãé¡äŒŒã®ä¿è·äœçšãçºæ®ãããšèããããŠããŸãã
ð é£åæº
ã»èµ€ã¯ã€ã³ïŒãã ã飲ã¿ããæ³šæïŒ
ã»ãã«ãŒããªãŒã»ãããŠ
ã»ããŒã¯ãã§ã³ã¬ãŒãïŒ70%以äžïŒ
ã»ç·è¶ã»çŽ
è¶
ð ãµããªã®å Žå
ã»ã¬ã¹ãã©ãããŒã«ïŒ100-500mg/æ¥
ã»ã±ã«ã»ãã³ïŒ500mg/æ¥
ã»ãã£ã»ãã³ïŒ100mg/æ¥
â»è溶æ§ã®ããé£äºãšäžç·ã«
ã¹ãã¬ã¹ç®¡çïŒæ ¢æ§ã¹ãã¬ã¹ã®åé¿ïŒ
ã³ã«ããŸãŒã«ã¯ãµãŒãã¥ã€ã³ã®æµ
ãªãéèŠãïŒ
æ¥æ§ã¹ãã¬ã¹ïŒéåã»æé£ã»å¯å·ïŒã¯ãµãŒãã¥ã€ã³ã掻æ§åããŸãããæ
¢æ§çãªå¿ççã¹ãã¬ã¹ã¯é广ãã³ã«ããŸãŒã«ã®æç¶çäžæã¯NAD+代è¬ãä¹±ããççãä¿é²ãããµãŒãã¥ã€ã³ã®æ©èœãé»å®³ããŸãã
ð§ æšå¥š
ã»çæ³ïŒ1æ¥10-20å
ã»æ·±åŒåžïŒ4-7-8åŒåžæ³
ã»èªç¶ã®äžã§ã®æé
ã»ç€ŸäŒçã€ãªããã®ç¶æ
â ïž é¿ããã¹ãããš
ã»æ
¢æ§çãªç¡ç äžè¶³
ã»é床ã®ä»äºã»å®ç§äž»çŸ©
ã»å€ç«ã»ç€ŸäŒçæçµ¶
ã»è§£æ±ºã§ããªãåé¡ã®åè»
ð 7ã€ã®æ¹æ³ïŒå¹æãšå®è·µé£æåºŠã®æ¯èŒ
| æ¹æ³ | 广 | é£æåºŠ | ã³ã¹ã | ãããã床 |
|---|---|---|---|---|
| æé£ã»ã«ããªãŒå¶é | â â â â â | äžãé« | ç¡æ | â |
| éåïŒHIITçïŒ | â â â â â | äž | äœãäž | â |
| NMN/NRãµã㪠| â â â â â | äœ | é« | â |
| å¯å·åºæ¿ | â â â ââ | é« | ç¡æ | â |
| è¯è³ªãªç¡ç | â â â â â | äœ | ç¡æ | â |
| ããªãã§ããŒã« | â â â ââ | äœ | äœãäž | â |
| ã¹ãã¬ã¹ç®¡ç | â â â â â | äž | ç¡æ | â |
ð 5. NMNãµããªã¡ã³ãã®çå®ââ广ã»å¯äœçšã»éžã³æ¹
NMNãµããªã¯ãè¥è¿ããµããªããšããŠå€§ããªæ³šç®ãéããŠããŸãããæ¬åœã«å¹ãã®ãïŒå®å šãªã®ãïŒç§åŠçãšããã³ã¹ãå·éã«æ€èšŒããŸãã
â ç§åŠçã«ç¢ºèªãããŠããããš
1. NMNã¯NAD+ãå¢å ãããïŒããèšåºè©Šéšã§ç¢ºèªæžã¿ïŒYoshino et al., Science 2021ïŒ
2. çæçãªå®å
šæ§ïŒ250-1200mg/æ¥ã§12é±éã®æäžã¯å®å
šïŒè€æ°ã®èšåºè©ŠéšïŒ
3. äžéšã®ä»£è¬ææšæ¹åïŒçèã®ã€ã³ã¹ãªã³æåæ§åäžãå ±åïŒéçµåŸå¥³æ§å¯Ÿè±¡ïŒ
4. éåèæ§ã®åäžïŒäžé«å¹Žè
ã®æé
žçŽ èœåæ¹åïŒäžéšç ç©¶ïŒ
â ïž ãŸã ããã£ãŠããªãããšã»æ³šæç¹
1. é·æçãªå®å
šæ§ïŒ5幎ã10幎ã®é·ææäžã®åœ±é¿ã¯äžæ
2. 寿åœå»¶é·å¹æïŒããã§ã寿åœãå»¶ã³ãããšããããŒã¿ã¯ãŸã ãªã
3. ãããžã®åœ±é¿ïŒäžéšã®ç ç©¶ã§ãã现èãNAD+ãå©çšãããšã®ææ
4. æé©ãªçšéïŒå人差ã倧ãããäžäººã«æé©ãªéã¯ç¢ºç«ãããŠããªã
5. 補åã®å質ïŒèŠå¶ãç·©ããçŽåºŠã»å«æéãäžæ£ç¢ºãªè£œåãååš
ðšâð¬ David Sinclairææèªèº«ã®æåå 容ïŒå ¬éæ å ±ïŒ
ã»NMNïŒ1g/æ¥ïŒæããšãŒã°ã«ããšäžç·ã«ïŒ
ã»ã¬ã¹ãã©ãããŒã«ïŒ1g/æ¥ïŒè溶æ§ã®ããèèªãšäžç·ã«ïŒ
ã»ã¡ããã«ãã³ïŒ1g/æ¥ïŒç³å°¿ç
æ²»çè¬ãåŠæ¹ç®ãå¿
èŠïŒ
ã»ãã¿ãã³D3ã»K2
ã»16:8æé£ãå®è·µ
ã»å®æçãªéå
â»ããã¯Sinclairå人ã®éžæã§ãããå»åŠçãªæšå¥šã§ã¯ãããŸããã
ð NMNãµããªãéžã¶ãªãïŒãã§ãã¯ãã€ã³ã
1. 第äžè
æ€æ»æžã¿ïŒçŽåºŠã»å«æéã第äžè
æ©é¢ã§æ€èšŒãããŠããã
2. β-NMNïŒÎ²åïŒçäœæŽ»æ§åïŒã§ããããšã確èª
3. åœç£ or ä¿¡é Œã§ãããã©ã³ãïŒè£œé éçšãéæãªã¡ãŒã«ãŒ
4. é®å
ã»å¯å°å
è£
ïŒNMNã¯å
ã»ç±ã»æ¹¿æ°ã«åŒ±ã
5. äŸ¡æ Œãæ¥µç«¯ã«å®ããªãïŒå䟡ãé«ããããå®ããããã®ã¯çå
âïž 6. éå vs ãµã㪠vs æé£ïŒã©ããæã广çãïŒ
ãNMNã飲ãã ãã§è¥è¿ãããªã楜ãªã®ã«âŠããšæã人ãå€ãã§ããããã§ã¯ãéåã»ãµããªã»æé£ãæ¯èŒãããšããã©ããæã广çãïŒç§åŠçèŠå°ããåæããŸãã
ð ãµãŒãã¥ã€ã³æŽ»æ§åã¡ãœããæ¯èŒ
| è©äŸ¡é ç® | ð éå | ðœïž æé£ | ð NMNãµã㪠|
|---|---|---|---|
| ãµãŒãã¥ã€ã³æŽ»æ§å | â â â â â | â â â â â | â â â â â |
| ãšããã³ã¹ã®ç¢ºå®æ§ | â â â â â | â â â â â | â â â ââ |
| 坿¬¡ç广 | çèã»å¿èºã»è³ | ãªãŒããã¡ãžãŒã»æžé | NAD+ã®ã¿ |
| ã³ã¹ã | äœãäž | ç¡æ | é«ïŒæ1-3äžåïŒ |
| ç¶ç¶ãããã | äžïŒç¿æ £åå¿ èŠïŒ | äžïŒç©ºè ¹ãšã®æŠãïŒ | é«ïŒé£²ãã ãïŒ |
ð çµè«ïŒæã广çãªã®ã¯ãçµã¿åããã
ãµããªã ããéåã ãã§ã¯ãªããè€æ°ã®ã¢ãããŒããçµã¿åãããããšã§
çžä¹å¹æãçãŸãããµãŒãã¥ã€ã³æŽ»æ§ãæå€§åãããŸãã
ãŽãŒã«ãã¹ã¿ã³ããŒãïŒ
ð éåïŒé±3å以äžïŒ + ðœïž 16æéæé£ + ðŽ è¯è³ªãªç¡ç
â ãããåºç€ãäœè£ãããã°ãµããªã远å
ð 7. 仿¥ããå§ããããµãŒãã¥ã€ã³æŽ»æ§åã«ãŒãã£ã³ã
çè«ã¯ååãããããã¯å ·äœçãªã¢ã¯ã·ã§ã³ãã©ã³ã§ããåå¿è ã§ãå§ããããããµãŒãã¥ã€ã³æŽ»æ§åã«ãŒãã£ã³ãã3段éã§ã玹ä»ããŸãã
åå¿è åãïŒãŸãã¯ãããã
ð æã®ã«ãŒãã£ã³
⢠æé£ã1æéé
ãããïŒ12æéæé£ã«ïŒ
â¢ ææ¥ã10åæµŽã³ã
⢠ã³ãã1æ¯ã®æ°Žã飲ã
ð å€ã®ã«ãŒãã£ã³
⢠å€é£ã20æãŸã§ã«çµãã
⢠22æä»¥éã¯ã¹ããããªã
⢠23æãŸã§ã«å°±å¯
äžçŽè åãïŒç¿æ £åããã
ðœïž é£äº
⢠16:8æé£ãå°å
¥
⢠é±2-3åã®ééïŒãªã¡ã¬3ïŒ
⢠ããªãŒé¡ã»ç·è¶ãç¿æ
£ã«
ðïž éå
⢠é±3åã®éåïŒHIIT or çãã¬ïŒ
⢠空è
¹ç¶æ
ã§ã®æéå
⢠é±1åã®å·æ°Žã·ã£ã¯ãŒïŒæåŸ30ç§ïŒ
äžçŽè åãïŒæå€§åãç®æããªã
ð ãµããªã¡ã³ã
⢠NMNïŒ250-500mg/æ¥ïŒæïŒ
⢠ã¬ã¹ãã©ãããŒã«ïŒ100-500mgïŒé£äºãšïŒ
⢠ãã¿ãã³D3ïŒ2000-4000IU/æ¥
ð ã¢ãã¿ãªã³ã°
â¢ å®æçãªè¡æ¶²æ€æ»ïŒNAD+ãççããŒã«ãŒïŒ
⢠çç©åŠç幎霢ãã¹ãïŒDNAã¡ãã«åïŒ
⢠é±1åã®24æéæé£
âš 8. ãŸãšãïŒèåã¯éžæã§ãã
ãµãŒãã¥ã€ã³éºäŒåã®çºèŠã¯ããèåãã«å¯Ÿããç§ãã¡ã®èªèãæ ¹æ¬ããå€ããŸãããèåã¯é¿ããããªãéåœã§ã¯ãªããããçšåºŠã³ã³ãããŒã«å¯èœãªããã»ã¹ãªã®ã§ãã
ð æ¬èšäºã®ãŸãšã
â ãµãŒãã¥ã€ã³éºäŒåã¯ãDNA修埩ã»ä»£è¬èª¿æŽã»ççæå¶ãæ
ãã现èã®å®è·è
ã
â NAD+ãçæã§ãããå 霢ãšãšãã«æžå°ãã
â æŽ»æ§åæ¹æ³ã¯ïŒæé£ãéåãNMNãµããªãå¯å·åºæ¿ãç¡ç ãããªãã§ããŒã«ãã¹ãã¬ã¹ç®¡ç
â NMNãµããªã¯ææã ããé·æçãªå¹æã»å®å
šæ§ã¯ãŸã ç 究段é
â æã广çãªã®ã¯ãéåïŒæé£ïŒç¡ç ãã®çµã¿åãã
â 仿¥ããå§ããããç¿æ
£ã§ããµãŒãã¥ã€ã³ã¯æŽ»æ§åã§ãã
ââ æåŸã« ââ
ããã€ãèå察çãå§ããããã§ã¯ãªã
仿¥ã®éžæãã10幎åŸã®ããªããäœã
é«äŸ¡ãªãµããªãè²·ãåã«ã仿¥ã§ããããšããããŸãã
å€é£ã1æéæ©ãçµãããæ10åæ©ãèµ·ããŠæ©ãã22æã«ã¹ããã眮ãã
ããªãã®ãµãŒãã¥ã€ã³ã¯ãããªãã®è¡åãåŸ
ã£ãŠããŸãã
ââ ç§åŠçã¢ãããŒãã§äœãå€ãã ââ
åºåŒµããã¯ãã¯ã·ã³ã° à åºåŒµããŒãœãã«ãã¬ãŒãã³ã°
ãµãŒãã¥ã€ã³éºäŒåãæŽ»æ§åããæåŒ·ã®éåïŒé«åŒ·åºŠã€ã³ã¿ãŒãã«ãã¬ãŒãã³ã°ã
ããã¯ãã¯ã·ã³ã°ã¯ãæé
žçŽ Ãçãã¬Ãæ°ããåãã®ç¿åŸãåæã«è¡ãããçæ³çãªéåã§ãã
èªå®
ã»ãªãã£ã¹ã«ãããã¬ãŒããŒã蚪åããããªãå°çšã®ããã°ã©ã ãèšèšããŸãã
⻠匷åŒãªå§èªã¯äžåãããŸããããŸãã¯ãæ°è»œã«ãçžè«ãã ããã
ð åèæç®ã»ãšããã³ã¹ãœãŒã¹
[1] Sinclair DA, LaPlante MD. “Lifespan: Why We Ageâand Why We Don’t Have To.” Atria Books, 2019
[2] Guarente L. “Sirtuins, aging, and metabolism.” Cold Spring Harb Symp Quant Biol. 2011
[3] Imai S, Guarente L. “NAD+ and sirtuins in aging and disease.” Trends Cell Biol. 2014
[4] Cantó C, et al. “AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.” Nature. 2009
[5] Yoshino J, et al. “NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.” Cell Metab. 2018
[6] Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021
[7] Kanfi Y, et al. “The sirtuin SIRT6 regulates lifespan in male mice.” Nature. 2012
[8] Haigis MC, Sinclair DA. “Mammalian sirtuins: biological insights and disease relevance.” Annu Rev Pathol. 2010
ð é¢é£ããŒã¯ãŒã
ãµãŒãã¥ã€ã³éºäŒå é·å¯¿éºäŒå NMN ãµããª å¹æ NAD+ å¢ããæ¹æ³ èå é転 æé£ ã¢ã³ããšã€ãžã³ã° HIIT 广 ãããã ã·ã³ã¯ã¬ã¢ åºåŒµããŒãœãã«ãã¬ãŒãã³ã° åºåŒµããã¯ãã¯ã·ã³ã°
â» æ¬èšäºã¯ç§åŠç ç©¶ã«åºã¥ãäžè¬çãªå¥åº·æ
å ±ãæäŸãããã®ã§ãããå»çã¢ããã€ã¹ã§ã¯ãããŸããã
ãµããªã¡ã³ãã®æåãæé£ãå§ããåã«ãå»åž«ã«ãçžè«ãã ããã
ïŒ 315fhgdyâäŒæ±äŒŽæå
¬åŒã¢ã«ãŠã³ãç»é²åŸã¹ã©ã€ãåžæorç»é²å²åŒåžæãšã³ã¡ã³ãäžããã
ð€é³å£°ããããŸãðµ

ã³ã¡ã³ã